406 related articles for article (PubMed ID: 24144415)
41. In vitro and in vivo trypanocidal activity of the ethyl esters of N-allyl and N-propyl oxamates using different Trypanosoma cruzi strains.
Aguirre-Alvarado C; Zaragoza-Martínez F; Rodríguez-Páez L; Nogueda B; Baeza I; Wong C
J Enzyme Inhib Med Chem; 2007 Apr; 22(2):227-33. PubMed ID: 17518350
[TBL] [Abstract][Full Text] [Related]
42. Molecular dynamics simulations of peptide inhibitors complexed with Trypanosoma cruzi trypanothione reductase.
Silva Da Rocha Pita S; Batista PR; Albuquerque MG; Pascutti PG
Chem Biol Drug Des; 2012 Oct; 80(4):561-71. PubMed ID: 22702225
[TBL] [Abstract][Full Text] [Related]
43. Effects of nifurtimox and benznidazole upon glutathione and trypanothione content in epimastigote, trypomastigote and amastigote forms of Trypanosoma cruzi.
Maya JD; Repetto Y; Agosín M; Ojeda JM; Tellez R; Gaule C; Morello A
Mol Biochem Parasitol; 1997 May; 86(1):101-6. PubMed ID: 9178272
[No Abstract] [Full Text] [Related]
44. Drug resistance in Trypanosoma cruzi is not associated with amplification or overexpression of P-glycoprotein (PGP) genes.
Murta SM; dos Santos WG; Anacleto C; Nirdé P; Moreira ES; Romanha AJ
Mol Biochem Parasitol; 2001 Oct; 117(2):223-8. PubMed ID: 11606233
[No Abstract] [Full Text] [Related]
45. Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy.
Nogueira Silva JJ; Pavanelli WR; Gutierrez FR; Alves Lima FC; Ferreira da Silva AB; Santana Silva J; Wagner Franco D
J Med Chem; 2008 Jul; 51(14):4104-14. PubMed ID: 18570370
[TBL] [Abstract][Full Text] [Related]
46. Antichagasic activity of komaroviquinone is due to generation of reactive oxygen species catalyzed by Trypanosoma cruzi old yellow enzyme.
Uchiyama N; Kabututu Z; Kubata BK; Kiuchi F; Ito M; Nakajima-Shimada J; Aoki T; Ohkubo K; Fukuzumi S; Martin SK; Honda G; Urade Y
Antimicrob Agents Chemother; 2005 Dec; 49(12):5123-6. PubMed ID: 16304182
[TBL] [Abstract][Full Text] [Related]
47. In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi.
Soeiro Mde N; de Souza EM; da Silva CF; Batista Dda G; Batista MM; Pavão BP; Araújo JS; Aiub CA; da Silva PB; Lionel J; Britto C; Kim K; Sulikowski G; Hargrove TY; Waterman MR; Lepesheva GI
Antimicrob Agents Chemother; 2013 Sep; 57(9):4151-63. PubMed ID: 23774435
[TBL] [Abstract][Full Text] [Related]
48. Insights into Chagas treatment based on the potential of bacteriocin AS-48.
Martín-Escolano R; Cebrián R; Martín-Escolano J; Rosales MJ; Maqueda M; Sánchez-Moreno M; Marín C
Int J Parasitol Drugs Drug Resist; 2019 Aug; 10():1-8. PubMed ID: 30953804
[TBL] [Abstract][Full Text] [Related]
49. Peptoid inhibition of trypanothione reductase as a potential antitrypanosomal and antileishmanial drug lead.
Chan C; Yin H; McKie JH; Fairlamb AH; Douglas KT
Amino Acids; 2002 Jun; 22(4):297-308. PubMed ID: 12107758
[TBL] [Abstract][Full Text] [Related]
50. [Experimental study on the therapeutic action of Ro 7-1051 on infections caused by different strains of Trypanosoma cruzi].
Andrade SG; Figueira RM
Rev Inst Med Trop Sao Paulo; 1977; 19(5):335-41. PubMed ID: 416483
[No Abstract] [Full Text] [Related]
51. The efficacy of a novel compound, (e)-1-(4'-bromo-4-biphenylyl)-1-(4-chlorophenyl)-3-dimethylaminoprop-1-ene against Trypanosoma cruzi in mice.
Barrett PA; Beveridge E; Bull D; Caldwell IC; Islip PJ; Neal RA; Woods NC
Experientia; 1982 Mar; 38(3):338-9. PubMed ID: 6804255
[TBL] [Abstract][Full Text] [Related]
52. [Biochemical bases of the action of anti-chagasic drugs].
Morello A; Aldunate J; Letelier ME; Repetto Y
Arch Biol Med Exp; 1988 Jun; 21(1):93-9. PubMed ID: 3154870
[No Abstract] [Full Text] [Related]
53. [Part VI. Antiparasitic treatment for Chagas disease].
B WA; G IH; L MI; M LJ; V PM; H IN; V AM; P JS; H MT; A IZ
Rev Chilena Infectol; 2008 Oct; 25(5):384-9, discussion 387. PubMed ID: 18949153
[TBL] [Abstract][Full Text] [Related]
54. Role of nucleic acid amplification assays in monitoring treatment response in chagas disease: Usefulness in clinical trials.
Sulleiro E; Muñoz-Calderon A; Schijman AG
Acta Trop; 2019 Nov; 199():105120. PubMed ID: 31376368
[TBL] [Abstract][Full Text] [Related]
55. Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts.
Guedes PM; Urbina JA; de Lana M; Afonso LC; Veloso VM; Tafuri WL; Machado-Coelho GL; Chiari E; Bahia MT
Antimicrob Agents Chemother; 2004 Nov; 48(11):4286-92. PubMed ID: 15504854
[TBL] [Abstract][Full Text] [Related]
56. Selective activity of 2,4-diaryl-1,2,3,4-tetrahydroquinolines on Trypanosoma cruzi epimastigotes and amastigotes expressing β-galactosidase.
Fonseca-Berzal C; Merchán Arenas DR; Romero Bohórquez AR; Escario JA; Kouznetsov VV; Gómez-Barrio A
Bioorg Med Chem Lett; 2013 Sep; 23(17):4851-6. PubMed ID: 23899616
[TBL] [Abstract][Full Text] [Related]
57. Novel N,N-di-alkylnaphthoimidazolium derivative of β-lapachone impaired Trypanosoma cruzi mitochondrial electron transport system.
Bombaça ACS; Silva LA; Chaves OA; da Silva LS; Barbosa JMC; da Silva AM; Ferreira ABB; Menna-Barreto RFS
Biomed Pharmacother; 2021 Mar; 135():111186. PubMed ID: 33395606
[TBL] [Abstract][Full Text] [Related]
58. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes.
Wilkinson SR; Taylor MC; Horn D; Kelly JM; Cheeseman I
Proc Natl Acad Sci U S A; 2008 Apr; 105(13):5022-7. PubMed ID: 18367671
[TBL] [Abstract][Full Text] [Related]
59. Novel scaffolds for inhibition of Cruzipain identified from high-throughput screening of anti-kinetoplastid chemical boxes.
Salas-Sarduy E; Landaburu LU; Karpiak J; Madauss KP; Cazzulo JJ; Agüero F; Alvarez VE
Sci Rep; 2017 Sep; 7(1):12073. PubMed ID: 28935948
[TBL] [Abstract][Full Text] [Related]
60. Research for new antichagasic drugs.
Mester B; Claramunt RM; Elguero J; Atienza J; Gómez Barrio A; Escario JA
Chem Pharm Bull (Tokyo); 1991 Aug; 39(8):1990-3. PubMed ID: 1797419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
